SNORD114-30: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD114-30

NCBI ID: G767611

SNORD114-30

Other Name(s): Small nucleolar RNA, C/D box 114-30 | 14q(II-30) | small nucleolar RNA, C/D box 114-30

SNORD114-30: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help maintain the stability of the nuclear envelope, which is a double membrane that surrounds the nucleus and plays a vital role in the regulation of cell signaling and interactions. MBND (Mammalian body network database) contains 1,662 known snRNAs and many more are undiscovered.

SNORD114-30 is a specific snRNA molecule that is located within the C/D box 114-30 of the 28S rRNA molecule. It is a 22-nt RNA molecule that contains 7-8 base pairs. The C/D box is a region of the rRNA molecule that contains a specific sequence that is involved in the formation of the double helix. The 114-30 position is located in the middle of the C/D box and is part of the 3' end of the rRNA molecule.

SNORD114-30 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in the regulation of gene expression. The C/D box region of SNORD114-30 is known for its role in the formation of the double helix, which is a critical step in the regulation of gene expression. This region is also known for its ability to interact with other RNA molecules, such as the protein HuR (hub protein with RNA binding motif), which is known to play a role in the regulation of gene expression and the stability of the nuclear envelope.

The potential drug target for SNORD114-30 is the regulation of gene expression, specifically the regulation of the stability of the nuclear envelope. The disruption of the normal function of the nuclear envelope has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the regulation of the stability of the nuclear envelope by SNORD114-30 may be a promising target for the development of new therapeutic strategies.

In addition to its potential as a drug target, SNORD114-30 also has potential as a biomarker. The regulation of gene expression is a critical aspect of cellular biology, and the stability of the nuclear envelope is a critical factor in the regulation of gene expression. Therefore, the levels of SNORD114-30 may be an informative biomarker for a variety of cellular processes, including the regulation of gene expression and the stability of the nuclear envelope.

The identification of SNORD114-30 as a potential drug target and biomarker has important implications for the development of new therapeutic strategies. The regulation of gene expression by SNORD114-30 may be a promising target for the development of new anti-cancer drugs, as the disruption of the normal function of the nuclear envelope has been implicated in the development of a variety of cancers. In addition, the regulation of the stability of the nuclear envelope by SNORD114-30 may be a promising target for the development of new drugs that target neurodegenerative diseases.

In conclusion, SNORD114-30 is a unique and promising snRNA molecule that has the potential to be a drug target and biomarker. The regulation of gene expression by SNORD114-30 is a critical aspect of cellular biology, and the stability of the nuclear envelope is a critical factor in the regulation of gene expression. Therefore, the regulation of SNORD114-30 by

Protein Name: Small Nucleolar RNA, C/D Box 114-30

The "SNORD114-30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets